AMA to help docs cash in on EHR stimulus dollars

Share this article:
AMA to help docs cash in on EHR stimulus dollars
AMA to help docs cash in on EHR stimulus dollars

Doctors that demonstrate the "meaningful use" of electronic health records (EHR) in their practices are eligible for at least $44,000 over five years, an incentive the American Medical Association (AMA) is facilitating with a new partnership.

AMA's partnership with UnitedHealth-owned Ingenix will offer physicians a way to "assess and meet their clinical and practice needs," as well as "access information, products and services with a single, secure sign-on," according to an AMA release. The platform is currently in beta testing through a collaboration with the Michigan State Medical Society, and will launch nationwide later this year, according to the release.

The Ingenix CareTracker platform will also help physicians demonstrate meaningful use of an EHR system, the key qualification for payment under the American Reinvestment and Recovery Act, said Bill Miller, EVP, healthcare delivery systems at Ingenix in the release.

A survey conducted by Sermo and AthenaHealth, an EHR provider, found that 80% of responding Sermo docs view EHRs favorably, believing that they improve patient care. However, 90% of the docs surveyed said they agree or strongly agree that EHRs are expensive to purchase, and 60% agree or strongly agree that EHRs "distract from face to face interaction with patients," according to survey results.

"Discussion amongst the Sermo physician community supports the survey's findings of 'holes' in current offerings and more broadly the notion that EHRs have a long way to go towards delivering on the promise of cost savings, freed resources, and better medicine," said Daniel Palestrant, Sermo CEO, in a statement.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...